New stem cell collection strategy aims to reduce transplant complications
NCT ID NCT07188090
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new approach to collect stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. Instead of giving everyone the drug plerixafor, doctors will start with G-CSF alone and only add plerixafor if needed. The goal is to see if this method collects enough stem cells while possibly lowering the risk of engraftment syndrome, a complication that can cause fever, rash, and diarrhea after transplant. About 100 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Plerixafor (also called Mozobil) and G-CSF (filgrastim or peg-filgrastim)
- What this could lead to
- If successful, this approach could make stem cell collection safer and more efficient for patients with multiple myeloma or lymphoma, reducing complications after transplant.
- What could go wrong
- This is a Phase 2 trial with only 100 participants, so results are preliminary. The strategy may not collect enough stem cells or may not lower engraftment syndrome risk as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?